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Assessment of Filled Buprenorphine Prescriptions
for Opioid Use Disorder During
the Coronavirus Disease 2019 Pandemic
The coronavirus disease 2019 (COVID-19) pandemic has
profoundly disrupted health care delivery in the US.1 The
Centers for Disease Control and Prevention noted a 9.1%
increase in reported 12-month counts of drug overdose deaths
from March 2019 to March 2020, from 67 726 to 73 860.2
On March 13, 2020, a COVID-19 national emergency was
declared. To diminish potential barriers to treatment access,
3 days later, federal guidelines on telemedicine use were re-
leased, providing authorized practitioners increased flexibil-
ity to prescribe buprenorphine to patients with opioid use dis-
order (OUD) during this public health emergency.3 Other local,
state, and federal policy initiatives have also attempted to pre-
serve access to medication treatment for OUD, yet the cumu-
lative outcome of these undertakings is not clear.
Methods | Using retail pharmacy claims from Symphony
Health, US database that includes 92% of retail pharmacy
claims,4 we examined secular trends of total US retail phar-
macy sales and sales of buprenorphine products with a US
Food and Drug Administration–approved indication for treat-
ment of OUD.5 We counted the number of individuals who
filled prescriptions in each week between May 1, 2019, and
June 28, 2020, except for the week of March 8 to March 15,
2020, which was excluded because this was the week before
the transitioning week (March 16). The results were not sensi-
tive to analysis including this week.
We plotted the raw and fitted number of individuals fill-
ing prescriptions during the prepandemic and pandemic
periods. We defined the transition between these periods as
occurring on March 16, 2020, when the Substance Abuse
and Mental Health Services Administration and Drug
Enforcement Administration approved telemedicine use for
buprenorphine prescribing. We further stratified national
changes by payer, including Medicaid, Medicare Part D, com-
mercial plans, and prescriptions paid in cash. Using quasi-
experimental interrupted time series analysis, we examined
whether there was a change in the level or rate of growth
(slope) of filled prescriptions between the 2 periods. Data
analysis was conducted with Stata, version 16.1 (StataCorp
LLC), using 2-sided t tests for regressions, with significance
set at P < .05. The study was exempted from review by Indi-
ana University’s Institutional Review Board. Data were dei-
dentified. This study followed the Strengthening the Report-
ing of Observational Studies in Epidemiology (STROBE)
reporting guideline.
Results | The weekly number of individuals filling prescrip-
tions of buprenorphine indicated for OUD increased steadily
from 172 165 in May 2019 to 216 939 in March 2020—a 26.01%
increase. The weekly number of individuals filling prescrip-
tions of any type also increased steadily during this period,
albeit at a lower rate of 8.78% (Figure, A).
The weekly growth rate in the level of prescription fills for
buprenorphine significantly declined by 0.50% (95% CI,
−0.84% to −0.15%) between the prepandemic and pandemic
periods (Table). We found no statistically significant or sud-
den declines in the level of these prescriptions in March (in-
tercepts). In contrast to buprenorphine prescriptions, the pan-
demic period was associated with an abrupt and statistically
significant decline in both the level (−5.03 million, 95% CI,
−6.85 million to −3.20 million) and growth rate (−0.57%, 95%
CI, −1.01% to −0.14%) when considering all filled prescrip-
tions collectively.
Filled prescriptions for buprenorphine paid in cash sig-
nificantly declined in both the levels and growth rate in the
pandemic period; no significant changes were found in filled
prescriptions paid by Medicaid (Figure, B and Table). In gen-
eral, the changes in prescriptions paid by Medicare and com-
mercial plans followed the patterns described above for all
buprenorphine prescriptions.
Discussion | Our findings suggest that, since the COVID-19
national emergency declaration, the number of individuals
filling buprenorphine prescriptions has plateaued but has not
decreased; however, filled prescriptions for all medications
collectively have decreased considerably. Study limitations
include our inability to identify off-label prescribing, illicit
diversion, or dispensing of buprenorphine via opioid treat-
ment programs. In addition, we cannot precisely identify
treatment initiation vs continuation. Efforts to engage
patients with OUD via telehealth may have helped retain
patients who otherwise would have discontinued treatment.
It is also plausible that continued telehealth service provision
plays an important role in addressing the ongoing opioid cri-
sis. Given buprenorphine’s role in treating OUD, our findings
may contribute to a better understanding of the pandemic’s
association with the treatment of OUD.
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Figure. Weekly Averages of Individuals With Filled Prescriptions Before and During the Coronavirus Disease 2019 Pandemic
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Prepandemic fitted values (buprenorphine)
Prepandemic fitted values (all drugs)
Pandemic fitted values (buprenorphine)





Data from Symphony Health, a US database that includes 92% of retail
pharmacy claims, 71% of mail order pharmacy claims, and 65% of specialty
pharmacy activity. We counted the number of individuals who filled
prescriptions in each week between May 6, 2019, and June 28, 2020, except for
the week of March 8 to March 15, 2020, which was excluded because this was
the week before the transitioning week (March 16). We also excluded several
weeks with national holidays: November 26, 2019, December 24, 2019, and
January 1, 2020, to smooth the data. Buprenorphine prescriptions of 1 048 575
unique individuals were identified by the national drug codes of buprenorphine
products from the Centers for Disease Control and Prevention; 2 buprenorphine
products (Butrans and Belbuca) were excluded from the sample because they
are indicated for pain management.
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